Skip to main content

Table 3 Target therapy clinical trials related to phase II & III advanced or metastatic sarcoma

From: The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov

Targets Trials (n) %
Multi-RTK 40 31.3
VEGFR 17 13.3
mTOR 12 9.4
HDAC 9 7.0
Combination targets 8 6.3
CDK 6 4.7
IGF-1R 5 3.9
PDGFR 5 3.9
Hedgehog 3 2.3
AKT 2 1.6
CD105 2 1.6
EGFR 2 1.6
HER2 2 1.6
Hypoxic region 2 1.6
MET 2 1.6
26S proteasome 1 <1
Aurora A 1 <1
CRM1 1 <1
DR5 1 <1
Endoglin 1 <1
Endosialin/TEM1 1 <1
G6PD 1 <1
PPAR-γ 1 <1
SRC 1 <1
Tie2 1 <1
β-receptor 1 <1
  1. The different targets of 128 registered clinical trials. RTK, receptor tyrosine kinase; VEGFR, vascular endothelial growth factor receptor; HDAC, histone deacetylase; CDK, cyclin-dependent kinase; IGF-1R, insulin-like growth factor 1 receptor; PDGFR, platelet-derived growth factor receptor; AKT, protein kinase B; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; MET, a receptor tyrosine kinase that is produced as a single-chain precursor; CRM1, chromosomal maintenance 1; DR5, death receptor-5; G6PD, glucose-6-phosphate dehydrogenase; PPAR-γ, peroxisome proliferator-activated receptors; SRC, proto-oncogene tyrosine-protein kinase; Tie2, tyrosine kinase with immunoglobulin-like and EGF-like domains 1